Mesenchymal Stem Cell Therapy for Drug-Resistant Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy, particularly temporal lobe epilepsy, often fail to effectively control seizures in approximately 30% of patients, and there is a need for innovative methods to inhibit or reverse epilepsy and seizure disorders.
Innovation Solution
Administration of mesenchymal stem cells derived from various tissues, expressing specific markers, combined with anti-inflammatory and anti-epileptic drugs, to induce a therapeutic effect in patients, with methods including mobilization and isolation techniques using specific agents and antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-epileptic drugs are administered to control seizures, then seizure frequency may be reduced, but therapeutic effectiveness is insufficient in approximately 30% of epilepsy patients
Solution Approach 1:
The patent introduces mesenchymal stem cells as a biological intermediary that mediates therapeutic effects through multiple mechanisms including anti-inflammatory actions, neuroprotection, and modulation of epileptogenic networks. These cells serve as a bridge between conventional drug therapy and direct neurological intervention, providing enhanced and more adaptable treatment for drug-resistant epilepsy cases
2Reliability
If conventional epilepsy treatments are used, then treatment simplicity is maintained, but therapeutic outcome is inadequate for chronic epilepsy management
Solution Approach 1:
The treatment approach is segmented into distinct phases: (1) administration of mesenchymal stem cells, (2) co-administration or subsequent administration of anti-inflammatory drugs, and (3) subsequent administration of anti-epileptic drugs. This segmentation allows each component to be optimized independently while working synergistically to achieve superior therapeutic outcomes in chronic epilepsy management
3Reliability
If mesenchymal stem cell therapy is administered, then potential for reversing epilepsy is enhanced, but treatment protocol complexity increases due to multiple administration steps
Solution Approach 1:
Mesenchymal stem cells are administered in advance to establish a therapeutic foundation before anti-epileptic drugs are introduced. This preliminary action allows the stem cells to exert their neuroprotective and anti-inflammatory effects, creating a more favorable environment for subsequent drug therapy and potentially reducing the complexity of long-term management
Data Source
AI summary
Disclosed are novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes. In one embodiment umbilical cord mesenchymal stem cells are administered to a patient suffering from epilepsy at a concentration and frequency sufficient to inhibit neuronal hyperactivation and/or reduce neuroinflammatory status of the patient